DXCM Financial Facts
Research and development: 43.9MInterest expense: -200K
See Full Income Statement
Short-term marketable securities, available-for-sale: 29.6M
Additional paid-in capital: 876M
See Full Balance Sheet
DexCom, Inc. (DXCM) Earnings
|
Expand Research on DXCM
| Next EPS Date | 10/30/26 *Est. | EPS Growth Rate | +45.8% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +11.4% | Revenue Growth Rate | +12.9% *Last Qtr. |
| Average % Move 1-Wk after EPS | +2.5% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 7/30/26 | Q226 | $0.70 | $0.61 | +$0.09 | $1.31B | $1.29B | = |  | | Details | |
| 4/30/26 | Q126 | $0.56 | $0.47 | +$0.09 | $1.19B | $1.17B | = | | | Details | |
| 2/12/26 | Q425 | $0.68 | $0.65 | +$0.03 | $1.26B | $1.24B | = | | | Details | |
| 10/30/25 | Q325 | $0.61 | $0.57 | +$0.04 | $1.21B | $1.18B | = | | | Details | |
| 7/30/25 | Q225 | $0.48 | $0.45 | +$0.03 | $1.16B | $1.12B | = | | | Details | |
| 5/1/25 | Q125 | $0.32 | $0.33 | -$0.01 | $1.04B | $1.02B | = | | | Details | |
| 2/13/25 | Q424 | $0.45 | $0.52 | -$0.07 | $1.11B | $1.1B | = | | | Details | |
| 10/24/24 | Q324 | $0.45 | $0.43 | +$0.02 | $994.2M | $990.44M | = | | | Details |
